MapLight director Malenka lists $207K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. (MPLT) director Robert Malenka listed 11,264 common shares for sale, with an approximate sale date of February 23, 2026 and an aggregate market value of $207,490.76.
The shares were acquired from the issuer on January 23, 2026 through restricted stock vesting under a registered plan, with services rendered as payment. The recent-sales table lists, among other transactions, 21,262 shares sold January 29, 2026 for gross proceeds of $394,469.63 and 12,116 shares sold February 13, 2026 for gross proceeds of $220,685.67.
Key Figures
Key Terms
Restricted stock vesting financial
Registered plan financial
Aggregate market value financial
Gross proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.